A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial - Wikidata - wikimedia - TriplyDB

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial

http://www.wikidata.org/entity/Q36607295

about

Prospects for dengue vaccines for travelers The dengue vaccine pipeline: Implications for the future of dengue control Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Vaccines and immunization strategies for dengue prevention Dengue: knowledge gaps, unmet needs, and research priorities Patterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strain Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificity In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines.Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4 Utility, limitations, and future of non-human primates for dengue research and vaccine development Dengue vaccines: recent developments, ongoing challenges and current candidates.Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.Dengue vaccines: strongly sought but not a reality just yet An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.The burden of dengue and chikungunya worldwide: implications for the southern United States and California Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.Economic Burden of Dengue Virus Infection at the Household Level Among Residents of Puerto Maldonado, Peru.Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine Challenges in reducing dengue burden; diagnostics, control measures and vaccines.An update on Zika vaccine developments.Developing a dengue vaccine: progress and future challenges.RNA-based viral vectors.A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.Dengue vaccines: what we know, what has been done, but what does the future hold?Vaccines licensed and in clinical trials for the prevention of dengue.Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans.

P2860

Q26314423-238FFDD1-15A3-4FDE-BD77-7413AA77120F Q26314683-E6C2E6F9-EB42-452D-B918-61FB32F257DF Q26782367-AA776858-5015-4FC4-A876-167F3B151E1E Q27654848-C6665EDC-C5DF-4E9C-910E-AE8C2DFDE8F2 Q28077521-3FA361C5-02B9-443A-854D-E4ED2E61A4A8 Q28729764-5A7F74CE-AB2B-4293-B071-91EC5F8B8AD6 Q28729784-2C42FEC7-3A6F-48D0-B8F2-D31D3360D7B0 Q28733418-01CDA227-7839-4241-A808-2606510A45AB Q30250977-CC58F3EA-C57B-4AF6-9155-2154ACD9CC4D Q33699057-BDE39586-B9F3-47BD-A8B7-D21E0B0BB66C Q33743890-2844497E-6765-40DF-8D6E-713F53F6818F Q33852635-43AA75F3-8A73-41E7-89CB-B6EFB017D4F8 Q34238916-9EEFA716-5141-4729-901D-75E4202BBDB3 Q34367194-771384BE-F3F1-467B-877F-07D649F5D9DB Q34522384-EF58BB29-AB37-4684-8120-F4B79A104580 Q34992520-2F3A24BD-A1AC-4676-840C-3A941BD339A8 Q35008771-E627B135-E68A-432C-BFE9-207CDD551CA3 Q35272502-3AAF1C61-CD51-49F7-B4A9-47E2DA5B3CDF Q35594746-C89A341B-1606-4E15-AC16-DFFC56AD6498 Q36024479-5CEADE97-5117-41BE-9DBF-5EAE936D5CD4 Q36131929-73156F41-E8FC-4F91-9EAE-95FC156DF758 Q36181531-5C09B982-FFA8-4E6C-BD34-58A40E8B3CD8 Q36288109-87FEDA0B-D9C4-45E4-8DD0-0687009063DB Q36307457-E7120243-0DD6-4038-A591-959880F93902 Q36846290-33E9DB5E-3DE6-4C69-AEBD-1AF362BC2571 Q37115807-3FC94591-0603-47EE-8DE5-1C4DEA81235F Q37184768-DB3061B3-07B9-4445-964A-AB8779A0293C Q37324444-61CC2DF0-BAF3-4E22-B438-379D2DE5CC2E Q37500519-EEFC9E13-B02B-4382-8CF1-C9A83E7EFB13 Q38140035-25BC0610-FB75-4F9F-9ACC-59D44F3A27B7 Q38158670-C3027987-5162-42B9-B66B-015C8BB76FF7 Q38201151-53C5B6DA-081F-4E25-A0C9-B53C1476FD66 Q38266413-B9D18987-F664-41C3-BC9A-57441F05EA58 Q38658737-4B56566A-F718-4798-B2A2-0C037C0B133E Q38960985-9AD2219E-4405-435E-80F5-361499E0F92D Q39172722-4570CB98-74E7-4591-972E-4EB3CF3C697B Q40040450-1A15F8BA-119B-478D-B55B-513B07F8CB1F Q40109446-6A7100A9-2371-4B9C-95D7-05227A172C23 Q40116968-9D9D8EAD-55AE-41E2-B85A-584AC5CB091D Q41924182-73D5E129-37B2-4EBD-BCC4-01688FC8ADBB

P2860

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial

http://www.wikidata.org/entity/Q36607295

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

A single dose of any of four d ...... d, double-blind clinical trial

@ast

A single dose of any of four d ...... d, double-blind clinical trial

@en

type

label

A single dose of any of four d ...... d, double-blind clinical trial

@ast

A single dose of any of four d ...... d, double-blind clinical trial

@en

prefLabel

A single dose of any of four d ...... d, double-blind clinical trial

@ast

A single dose of any of four d ...... d, double-blind clinical trial

@en

P1433

Q36607295-8213BCDA-6C4D-4634-8134-4E7201837D3A

P1476

Q36607295-7F587C06-81AE-4DAD-A5F4-487CB6D5CA28

P2093

Q36607295-2E67120B-D16D-456E-91E9-EDBC8A323FE5

Q36607295-44792BE7-B2B8-4819-AF54-F48003AD12B6

Q36607295-79C7FD2A-D47E-4CAC-A036-2A1C31D1B6B7

Q36607295-7B1EBC7F-AB9D-49E2-9CEA-A22AA41C6886

Q36607295-8503257B-10B4-4D8E-89C4-F4D6FD578986

Q36607295-911A0837-886B-4AE7-A847-EA1BCD7D8E23

Q36607295-91A2F447-E780-418F-8F41-39E9E7BE1879

Q36607295-972AC3EC-96D3-46DB-BB74-A9291BA1115B

Q36607295-A74D275D-347E-4B0F-8C59-4EC018450612

Q36607295-ADD65349-02A3-44E8-A007-A09A0FACF019

P2860

Q36607295-008EE5FE-8CB1-4D38-B473-03188C04702B

Q36607295-031ABC43-ACCA-4117-8536-886178584386

Q36607295-1184C97B-0F82-4712-9F70-16466458C89D

Q36607295-12FE894D-BD79-4A24-A2CB-0D0282086C59

Q36607295-15DE1665-C78B-4ACB-9809-83FA7B7954CB

Q36607295-180EF842-B0A1-430D-A918-B53352A7CB10

Q36607295-1BB0E492-2FF1-477D-8D6A-FB13889751BC

Q36607295-1D81A646-6EB5-4E5A-9D64-34ED7408BB24

Q36607295-1DD469F9-A3D4-4968-A05C-D75588BF69E9

Q36607295-25042553-DC9A-4B31-BB4B-C4687DDCFE05

P304

Q36607295-5CD33A78-ACCD-4CB5-8AB7-09370918D500

P31

Q36607295-2BA29568-86B5-4580-8DB0-D77B4B312B52

P356

Q36607295-4D8F1E8D-718E-4EBE-93A8-7C559DC6C03E

P407

Q36607295-DDC0D046-540E-4699-8019-97B924A978A3

P433

Q36607295-2E41F77E-E225-40B3-9751-EC23357EFA59

P478

Q36607295-2623C87E-0082-4103-B319-B2F96A23762A

P50

Q36607295-3C2EE071-3D73-484C-803F-3F65E1E6ACE4

Q36607295-4AD11F85-9D4B-4F1E-B44F-B1AAA8E029B9

Q36607295-BE478F0D-7D10-4CCD-A753-1D6870D56EBD

Q36607295-EBCF9809-B35C-4A0C-BC65-5D9838E12059

P577

Q36607295-CE3E2BFA-CA4E-4F7F-BE20-3637D1F49DC4

P5875

Q36607295-E5F5AFFE-CBB8-4D38-8D0F-08329E64D011

P698

Q36607295-9D1E3F75-668E-41CF-B7A3-56E333C08F2A

P921

Q36607295-873AA1ED-E863-4EFC-BAE3-44030DD80885

Q36607295-D8B39270-0301-4FF2-AC93-EB00FDF99360

P932

Q36607295-FA7B9188-58C5-41CC-AE24-2642F93DA5E8

P356

P1433

The Journal of Infectious Diseases

P1476

A single dose of any of four d ...... d, double-blind clinical trial

@en

P2093

Beth D Kirkpatrick

http://www.w3.org/2001/XMLSchema#string

Beulah P Sabundayo

http://www.w3.org/2001/XMLSchema#string

Brian R Murphy

http://www.w3.org/2001/XMLSchema#string

Catherine J Larsson

http://www.w3.org/2001/XMLSchema#string

Catherine J Luke

http://www.w3.org/2001/XMLSchema#string

Cecilia Tibery

http://www.w3.org/2001/XMLSchema#string

Daniel Elwood

http://www.w3.org/2001/XMLSchema#string

Donna Shaffer

http://www.w3.org/2001/XMLSchema#string

Kawsar R Talaat

http://www.w3.org/2001/XMLSchema#string

Kimberli Wanionek

http://www.w3.org/2001/XMLSchema#string

P2860

Oral immunization against poliomyelitis

Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

A prospective study of dengue infections in Bangkok

Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

Research on dengue during World War II

Impact of dengue/dengue hemorrhagic fever on the developing world.

P304

957-965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIS936

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

207

http://www.w3.org/2001/XMLSchema#string

P50

Janet C. Lindow

Stephen S Whitehead

P577

2013-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234162165

http://www.w3.org/2001/XMLSchema#string

P698

23329850

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

P932

3571448

http://www.w3.org/2001/XMLSchema#string